ARL6IP6

Across TCGA pan-cancer cohorts, ARL6IP6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARL6IP6 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARL6IP6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARL6IP6 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where ARL6IP6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.355	0.622	.001	43	view →
HNSC	DFS	Tertile	II,III,IV	0.802	0.571	.018	14	view →
LUAD	DFS	Quartile	III,IV	0.286	0.750	.008	10	view →
UCEC	DFS	Quartile	All	0.838	1.000	.035	4	view →
LSCC	OS	Quartile	All	0.947	0.830	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARL6IP6–PDAC (OS)

Open the PDAC breakdown →